NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pliant Therapeutics, Inc ("Pliant" or the "Company") (NASDAQ: PLRX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

PLANO, Texas, Feb. 25, 2025 (GLOBE NEWSWIRE) -- European Wax Center, Inc. (NASDAQ: EWCZ), the leading franchisor and operator of out-of-home waxing services in the United States, today announced that it plans to report fourth quarter and fiscal year 2024 financial results before the market opens on Tuesday, March 11, 2025. Following the release, the Company's management will host a conference call at 8:00 a.m. ET/7:00 a.m. CT to review the results.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Skyworks Solutions, Inc. ("Skyworks" or the "Company") (NASDAQ: SWKS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) between November 2, 2023 and October 30, 2024, both dates inclusive (the "Class Period"), of the important March 10, 2025 lead plaintiff deadline. So what: If you purchased Regeneron securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of NAPCO Security Technologies, Inc ("NAPCO" or the "Company") (NASDAQ: NSSC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Canopy Growth Corporation ("Canopy" or the "Company") (NASDAQ: CGC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of GeneDx Holdings Corp ("GeneDx" or the "Company") (NASDAQ: WGS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engineering revenue of $35 million in the fourth quarter of 2024, representing 29% growth over 2023 BOSTON , Feb. 25, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the fourth quarter and year ended December 31, 2024. The update, including a webcast slide presentation with additional details on the fourth quarter and full year, …

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Voyager Therapeutics, Inc ("Voyager" or the "Company") (NASDAQ: VYGR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Pagaya Technologies Ltd ("Pagaya" or the "Company") (NASDAQ: PGY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Company's fiscal year 2024 comparable store sales excluding fuel increased 1.9 percent SUNBURY, Pa. , Feb. 25, 2025 /PRNewswire/ -- Weis Markets, Inc. (NYSE: WMK) today reported its financial results for the 13-week fourth quarter and the 52-week fiscal year period ended December 28, 2024.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eldorado Gold Corporation ("Eldorado" or the "Company") (NYSE: EGO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Newmont Corporation ("Newmont" or the "Company") (NYSE:NEM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Edison International ("Edison" or the "Company") (NYSE:EIX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against FMC Corporation ("FMC" or the "Company") (NYSE:FMC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Fluence Energy, Inc ("Fluence" or the "Company") (NASDAQ: FLNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of STAAR Surgical Company ("STAAR" or the "Company") (NASDAQ: STAA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

NEW YORK , Feb. 25, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Harmonic Inc ("Harmonic" or the "Company") (NASDAQ: HLIT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

Fourth Quarter Financial Highlights Fourth quarter GAAP income from continuing operations was $102 million and GAAP diluted earnings per share from continuing operations was $0.77, inclusive of a non-cash $97.5 million favorable valuation allowance adjustment to deferred tax assets in the United States. Excluding unusual and non-recurring credits and expenses, adjusted income from continuing operations was $3.9 million, a 16% sequential improvement.

NEW YORK, NY / ACCESS Newswire / February 25, 2025 / If you suffered a loss on your Alarum Technologies Ltd. (NASDAQ:ALAR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/alarum-technologies-ltd-lawsuit-submission-form?prid=132185&wire=1 or contact Joseph E.